SiliconInvestor
     Advanced Search   [ sign in ]

register
Sponsor		  register
Register

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
From: Pistol Pete4/4/2012 2:06:50 PM
of 40233
 
Dendreon alternatives in the immunotherapy space. IMUC and GALE seem to be better positioned for growth at this time than DNDN. Looking at some of the recent news and trial results. The new generation of oncology biotechs seem to be creating better trial designs, developing higher margin/higher efficacy products, and ensuring manufacturing processes will be able to meet commercial demand.
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.